ciprofloxacin has been researched along with Body Weight in 35 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetic characteristics of ciprofloxacin were studied in 10 children with cystic fibrosis, aged from 6 to 16 years, who had completed the standard regimen of intravenous ceftazidime and amikacin." | 9.08 | Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ( Fischer, C; Hampel, B; Kuhlmann, J; Schaad, UB; Schaefer, HG; Stass, H; Wedgwood, J, 1996) |
| "Ciprofloxacin (CFX) implants containing poly(D,L-lactide) and calcium phosphates (tricalcium phosphate and hydroxyapatite) was evaluated in 50 rabbits in an experimental osteomyelitis model." | 7.74 | Efficacy of ciprofloxacin implants in treating experimental osteomyelitis. ( Alvarez, H; Castro, C; Delgado, A; Evora, C; Moujir, L; Perera, A; Sánchez, E; Soriano, I, 2008) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 5.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| " melitensis intraperitoneally on day 0 and were randomized to receive, starting on day 7, STR alone at 75, 150, or 300 mg/kg of body weight per day intraperitoneally or DOX at 6 mg/kg/day orally, RIF at 3 mg/kg/day orally, or CIP at 200 mg/kg/day orally, each of the last three drugs alone or in combination with STR at 75, 150, or 300 mg/kg/day, for 14 days." | 5.29 | Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. ( Lang, R; Rubinstein, E; Shasha, B, 1993) |
| "Ciprofloxacin did not inhibit collagen induced arthritis in adrenalectomized rats but rather caused an exacerbation of the disease." | 5.28 | Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. ( Breban, M; Fournier, C; Gougerot-Pocidalo, MA; Muffat-Joly, M; Pocidalo, JJ, 1992) |
| "The pharmacokinetic characteristics of ciprofloxacin were studied in 10 children with cystic fibrosis, aged from 6 to 16 years, who had completed the standard regimen of intravenous ceftazidime and amikacin." | 5.08 | Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients. ( Fischer, C; Hampel, B; Kuhlmann, J; Schaad, UB; Schaefer, HG; Stass, H; Wedgwood, J, 1996) |
| "For 3 weeks, we administered oral AB (ciprofloxacin/metronidazole) or control treatment to homozygous ΔF508 (Δ/Δ), cystic fibrosis transmembrane conductance regulator (CFTR) knockout (-/-), and wild-type (WT) mice and quantified fat absorption using a 72-h fat balance test." | 3.78 | Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis. ( Bijvelds, MJ; Burgerhof, JG; de Jonge, HR; De Lisle, RC; Verkade, HJ; Wouthuyzen-Bakker, M, 2012) |
| "The objective of this study was to analyze the relationship between pharmacokinetic parameters and body weight (W) for orbifloxacin using reported pharmacokinetic data." | 3.77 | Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis. ( Gebru, E; Kim, JC; Lee, SJ; Park, SC, 2011) |
| "Ciprofloxacin (CFX) implants containing poly(D,L-lactide) and calcium phosphates (tricalcium phosphate and hydroxyapatite) was evaluated in 50 rabbits in an experimental osteomyelitis model." | 3.74 | Efficacy of ciprofloxacin implants in treating experimental osteomyelitis. ( Alvarez, H; Castro, C; Delgado, A; Evora, C; Moujir, L; Perera, A; Sánchez, E; Soriano, I, 2008) |
| " On the other hand, ciprofloxacin, which is widely used in the treatment of infectious diseases, is known to cause hypoglycemia as a side effect." | 3.74 | [Influence of tacrolimus and ciprofloxacin on glucose metabolism]. ( Arai, S; Gouhara, T; Kihira, K; Kitaura, T; Miyake, K; Morita, S; Nagafuji, T; Sato, E; Tayama, Y, 2007) |
| "The aim of the present study was to characterize the population pharmacokinetics of ciprofloxacin in patients with and without cystic fibrosis ranging in age from 1 day to 24 years and to propose a limited sampling strategy to estimate individual pharmacokinetic parameters." | 3.72 | Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections. ( Aigrain, Y; Aujard, Y; Bressolle, F; Jacqz-Aigrain, E; Munck, A; Payen, S; Serreau, R, 2003) |
| " The associated risks of overdose for the proposed dosing regimen were <8%." | 2.79 | Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age. ( Castellan, C; Hill, H; Jacqz-Aigrain, E; Kassai, B; Kearns, GL; Le Guellec, C; Mahoney, S; Neal, T; Paulus, S; Turner, MA; van den Anker, JN; Zhao, W, 2014) |
| "Previous pharmacokinetic studies have shown that a number of the quinolones inhibit the metabolism of caffeine." | 2.71 | Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. ( Kim, MK; Nicolau, D; Nightingale, C, 2003) |
| "Ciprofloxacin pharmacokinetics exhibit interethnic variability, Asians exhibiting an increased bioavailability with regard to Mexicans and Caucasians." | 1.56 | Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability? ( Cabrera-Fuentes, HA; Castañeda-Hernández, G; Cruz-Antonio, L; Pérez-Urizar, J; Tolentino-Hernández, SJ, 2020) |
| "The antibiotic treatment rate of chronic bacterial prostatitis (CBP) is low, and long-term administration can result in adverse events and bacterial resistance." | 1.38 | Preventive effect of selenium on chronic bacterial prostatitis. ( Cho, YH; Ha, US; Kim, HW; Kim, SJ; Lee, SJ; Woo, JC; Yoon, BI, 2012) |
| "Obesity is a growing problem in the United States." | 1.38 | Underdosing of common antibiotics for obese patients in the ED. ( Fuentes, JM; Mullins, ME; Roe, JL, 2012) |
| " The bioavailability factor after oral administration was 0." | 1.36 | Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism. ( Chen, DM; Dai, MH; Fang, K; Guo, QJ; Huang, LL; Liu, ZL; Peng, DP; Tao, YF; Wang, YL; Yuan, ZH, 2010) |
| "In clinical development stages, an a priori assessment of the sensitivity of the pharmacokinetic behavior with respect to physiological and anthropometric properties of human (sub-) populations is desirable." | 1.34 | Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. ( Edginton, A; Höhn, K; Lippert, J; Schmitt, W; Sevestre, M; Solodenko, J; Weiss, W; Willmann, S, 2007) |
| " Population pharmacokinetic analyses were performed with NONMEN software." | 1.32 | Population pharmacokinetics of ciprofloxacin in pediatric patients. ( Gastonguay, MR; Rajagopalan, P, 2003) |
| " The results obtained showed that irloxacin was well tolerated after single administration in mice and rats, with LD50 values above 2000 and 5000 mg/kg for intraperitoneal and oral administration, respectively." | 1.30 | Acute and subchronic toxicity studies of the new quinolone antibacterial agent irloxacin in rodents. ( Demestre, I; García, C; Guzmán, A, 1999) |
| "2." | 1.30 | The comparative arthropathy of fluoroquinolones in dogs. ( Hashimoto, K; Minami, T; Owen, K; Takizawa, T; Yamashita, S, 1999) |
| " melitensis intraperitoneally on day 0 and were randomized to receive, starting on day 7, STR alone at 75, 150, or 300 mg/kg of body weight per day intraperitoneally or DOX at 6 mg/kg/day orally, RIF at 3 mg/kg/day orally, or CIP at 200 mg/kg/day orally, each of the last three drugs alone or in combination with STR at 75, 150, or 300 mg/kg/day, for 14 days." | 1.29 | Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin. ( Lang, R; Rubinstein, E; Shasha, B, 1993) |
| " If a dosage of 20 mg/kg/day was used, development of acute arthritis was prevented, but some of the animals had positive fecal cultures at the end of experiment." | 1.29 | Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. ( Gripenberg-Lerche, C; Söderström, KO; Toivanen, A; Toivanen, P; Zhang, Y, 1996) |
| " The bioavailability was 49%." | 1.29 | Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration. ( Abadía, AR; Aramayona, JJ; Bregante, MA; Llovería, P; Munoz, MJ; Santos, MP, 1996) |
| "Ciprofloxacin did not inhibit collagen induced arthritis in adrenalectomized rats but rather caused an exacerbation of the disease." | 1.28 | Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. ( Breban, M; Fournier, C; Gougerot-Pocidalo, MA; Muffat-Joly, M; Pocidalo, JJ, 1992) |
| " Pharmacokinetic and therapy studies of sparfloxacin were performed in guinea pigs with L." | 1.28 | In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. ( Dorr, MB; Edelstein, MA; Edelstein, PH; Weidenfeld, J, 1990) |
| " Pharmacokinetic parameters were calculated on a two compartment open model." | 1.27 | Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function. ( Asscher, AW; Roberts, DE; Webb, DB; Williams, JD, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.71) | 18.7374 |
| 1990's | 10 (28.57) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 10 (28.57) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Grime, K | 1 |
| Paine, SW | 1 |
| Chaturvedi, AK | 1 |
| Verma, AK | 1 |
| Thakur, JP | 1 |
| Roy, S | 1 |
| Bhushan Tripathi, S | 1 |
| Kumar, BS | 1 |
| Khwaja, S | 1 |
| Sachan, NK | 1 |
| Sharma, A | 1 |
| Chanda, D | 1 |
| Shanker, K | 1 |
| Saikia, D | 1 |
| Negi, AS | 1 |
| Tolentino-Hernández, SJ | 1 |
| Cruz-Antonio, L | 1 |
| Pérez-Urizar, J | 1 |
| Cabrera-Fuentes, HA | 1 |
| Castañeda-Hernández, G | 1 |
| Antonitsch, L | 1 |
| Weidinger, G | 1 |
| Stanek, G | 1 |
| Markowicz, M | 1 |
| Thi Quynh Nhi, L | 1 |
| Thanh Tuyen, H | 1 |
| Duc Trung, P | 1 |
| Do Hoang Nhu, T | 1 |
| Duy, PT | 1 |
| Hao, CT | 1 |
| Thi Thanh Nhan, N | 1 |
| Vi, LL | 1 |
| Thi Diem Tuyet, H | 1 |
| Thi Thuy Tien, T | 1 |
| Van Vinh Chau, N | 1 |
| Khanh Lam, P | 1 |
| Thwaites, G | 1 |
| Baker, S | 1 |
| Zhao, W | 1 |
| Hill, H | 1 |
| Le Guellec, C | 1 |
| Neal, T | 1 |
| Mahoney, S | 1 |
| Paulus, S | 1 |
| Castellan, C | 1 |
| Kassai, B | 1 |
| van den Anker, JN | 1 |
| Kearns, GL | 1 |
| Turner, MA | 1 |
| Jacqz-Aigrain, E | 2 |
| Guo, QJ | 1 |
| Huang, LL | 1 |
| Fang, K | 1 |
| Wang, YL | 1 |
| Chen, DM | 1 |
| Tao, YF | 1 |
| Dai, MH | 1 |
| Liu, ZL | 1 |
| Peng, DP | 1 |
| Yuan, ZH | 1 |
| Gebru, E | 1 |
| Lee, SJ | 3 |
| Kim, JC | 1 |
| Park, SC | 1 |
| Kim, HW | 2 |
| Ha, US | 2 |
| Woo, JC | 1 |
| Kim, SJ | 1 |
| Yoon, BI | 1 |
| Cho, YH | 2 |
| Roe, JL | 1 |
| Fuentes, JM | 1 |
| Mullins, ME | 1 |
| Wouthuyzen-Bakker, M | 1 |
| Bijvelds, MJ | 1 |
| de Jonge, HR | 1 |
| De Lisle, RC | 1 |
| Burgerhof, JG | 1 |
| Verkade, HJ | 1 |
| Kim, SH | 1 |
| Sohn, DW | 1 |
| Han, CH | 1 |
| Chansiripornchai, N | 1 |
| Sasipreeyajan, J | 1 |
| Rajagopalan, P | 1 |
| Gastonguay, MR | 1 |
| Kim, MK | 1 |
| Nightingale, C | 1 |
| Nicolau, D | 1 |
| Payen, S | 1 |
| Serreau, R | 1 |
| Munck, A | 1 |
| Aujard, Y | 1 |
| Aigrain, Y | 1 |
| Bressolle, F | 1 |
| Willmann, S | 1 |
| Höhn, K | 1 |
| Edginton, A | 1 |
| Sevestre, M | 1 |
| Solodenko, J | 1 |
| Weiss, W | 1 |
| Lippert, J | 1 |
| Schmitt, W | 1 |
| Alvarez, H | 1 |
| Castro, C | 1 |
| Moujir, L | 1 |
| Perera, A | 1 |
| Delgado, A | 1 |
| Soriano, I | 1 |
| Evora, C | 1 |
| Sánchez, E | 1 |
| Tayama, Y | 1 |
| Miyake, K | 1 |
| Nagafuji, T | 1 |
| Gouhara, T | 1 |
| Morita, S | 1 |
| Arai, S | 1 |
| Sato, E | 1 |
| Kitaura, T | 1 |
| Kihira, K | 1 |
| Caldwell, JB | 1 |
| Nilsen, AK | 1 |
| Lang, R | 1 |
| Shasha, B | 1 |
| Rubinstein, E | 1 |
| Linseman, DA | 1 |
| Hampton, LA | 1 |
| Branstetter, DG | 1 |
| Zhang, Y | 1 |
| Gripenberg-Lerche, C | 1 |
| Söderström, KO | 1 |
| Toivanen, A | 1 |
| Toivanen, P | 1 |
| Schaefer, HG | 1 |
| Stass, H | 1 |
| Wedgwood, J | 1 |
| Hampel, B | 1 |
| Fischer, C | 1 |
| Kuhlmann, J | 1 |
| Schaad, UB | 1 |
| Munoz, MJ | 1 |
| Llovería, P | 1 |
| Santos, MP | 1 |
| Abadía, AR | 1 |
| Aramayona, JJ | 1 |
| Bregante, MA | 1 |
| Guzmán, A | 2 |
| García, C | 2 |
| Demestre, I | 2 |
| Takizawa, T | 1 |
| Hashimoto, K | 1 |
| Minami, T | 1 |
| Yamashita, S | 1 |
| Owen, K | 1 |
| Hans, W | 1 |
| Schölmerich, J | 1 |
| Gross, V | 1 |
| Falk, W | 1 |
| Pispirigos, K | 1 |
| Chrysanthopoulos, K | 1 |
| Breban, M | 1 |
| Fournier, C | 1 |
| Gougerot-Pocidalo, MA | 1 |
| Muffat-Joly, M | 1 |
| Pocidalo, JJ | 1 |
| Edelstein, PH | 1 |
| Edelstein, MA | 1 |
| Weidenfeld, J | 1 |
| Dorr, MB | 1 |
| Ullmann, U | 1 |
| Giebel, W | 1 |
| Dalhoff, A | 1 |
| Koeppe, P | 1 |
| Webb, DB | 1 |
| Roberts, DE | 1 |
| Williams, JD | 1 |
| Asscher, AW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies[NCT03113344] | 800 participants (Anticipated) | Observational [Patient Registry] | 2017-06-21 | Recruiting | |||
| Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases[NCT03643497] | 800 participants (Anticipated) | Observational [Patient Registry] | 2018-07-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for ciprofloxacin and Body Weight
| Article | Year |
|---|---|
Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Topics: Anti-Bacterial Agents; Area Under Curve; Body Weight; Cardiotonic Agents; Chromatography, High Press | 2014 |
Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Topics: Anti-Bacterial Agents; Area Under Curve; Body Weight; Cardiotonic Agents; Chromatography, High Press | 2014 |
Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Topics: Anti-Bacterial Agents; Area Under Curve; Body Weight; Cardiotonic Agents; Chromatography, High Press | 2014 |
Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
Topics: Anti-Bacterial Agents; Area Under Curve; Body Weight; Cardiotonic Agents; Chromatography, High Press | 2014 |
Efficacy of sarafloxacin in broilers after experimental infection with Escherichia coli.
Topics: Animals; Anti-Infective Agents; Body Weight; Chickens; Ciprofloxacin; Dose-Response Relationship, Dr | 2002 |
Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Topics: Administration, Oral; Adult; Area Under Curve; Body Weight; Caffeine; Ciprofloxacin; Cross-Over Stud | 2003 |
Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
Topics: Administration, Oral; Adolescent; Aging; Anti-Infective Agents; Biotransformation; Blood Proteins; B | 1996 |
31 other studies available for ciprofloxacin and Body Weight
| Article | Year |
|---|---|
Species differences in biliary clearance and possible relevance of hepatic uptake and efflux transporters involvement.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
A novel synthesis of 2-arylbenzimidazoles in molecular sieves-MeOH system and their antitubercular activity.
Topics: Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Binding Sites; Body Weight | 2018 |
Oral Ciprofloxacin Pharmacokinetics in Healthy Mexican Volunteers and Other Populations: Is There Interethnic Variability?
Topics: Administration, Oral; Adult; Asian People; Biological Availability; Body Weight; Ciprofloxacin; Ethn | 2020 |
Francisella tularensis as the cause of protracted fever.
Topics: Abdominal Pain; Anti-Bacterial Agents; Body Weight; Ceftriaxone; Ciprofloxacin; Cough; Diagnosis, Di | 2020 |
Excess body weight and age associated with the carriage of fluoroquinolone and third-generation cephalosporin resistance genes in commensal Escherichia coli from a cohort of urban Vietnamese children.
Topics: Age Factors; Anti-Bacterial Agents; Body Weight; Carrier State; Child, Preschool; Ciprofloxacin; Dru | 2018 |
Population pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in chicken based on retrospective data, incorporating first-pass metabolism.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Body Weight; Chickens; Ciprofloxacin; Enrofloxacin | 2010 |
Allometric scaling of orbifloxacin disposition in nine mammal species: a retrospective analysis.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Ciprofloxacin; Female; Half-Life; Male; Mammals; Regres | 2011 |
Preventive effect of selenium on chronic bacterial prostatitis.
Topics: Animals; Body Weight; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Escherichia coli; Esc | 2012 |
Underdosing of common antibiotics for obese patients in the ED.
Topics: Anti-Bacterial Agents; Bacterial Infections; Body Weight; Cefazolin; Cefepime; Cephalosporins; Cipro | 2012 |
Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis.
Topics: Animals; Anti-Bacterial Agents; Bile Acids and Salts; Body Weight; Ciprofloxacin; Cystic Fibrosis; C | 2012 |
Preventive effect of ginsenoid on chronic bacterial prostatitis.
Topics: Animals; Anti-Bacterial Agents; Body Weight; Ciprofloxacin; Colony Count, Microbial; Inflammation; M | 2012 |
Population pharmacokinetics of ciprofloxacin in pediatric patients.
Topics: Administration, Oral; Adolescent; Age Factors; Anti-Infective Agents; Biological Availability; Body | 2003 |
Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bayes Theorem; Body Weight; Child; Child, Pr | 2003 |
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.
Topics: Adult; Age Factors; Algorithms; Body Height; Body Mass Index; Body Weight; Ciprofloxacin; Computer S | 2007 |
Efficacy of ciprofloxacin implants in treating experimental osteomyelitis.
Topics: Absorbable Implants; Animals; Anti-Infective Agents; Biocompatible Materials; Blood Platelets; Body | 2008 |
[Influence of tacrolimus and ciprofloxacin on glucose metabolism].
Topics: Animals; Anti-Infective Agents; Body Weight; Cell Survival; Cells, Cultured; Ciprofloxacin; Cricetin | 2007 |
Intravenous ciprofloxacin dosing in a morbidly obese patient.
Topics: Adipose Tissue; Bacterial Infections; Body Weight; Cellulitis; Ciprofloxacin; Humans; Infusions, Int | 1994 |
Therapy of experimental murine brucellosis with streptomycin alone and in combination with ciprofloxacin, doxycycline, and rifampin.
Topics: Animals; Body Weight; Brucella; Brucellosis; Ciprofloxacin; Colony Count, Microbial; Doxycycline; Dr | 1993 |
Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin.
Topics: Animals; Animals, Newborn; Anti-Infective Agents; Body Weight; Cartilage, Articular; Ciprofloxacin; | 1995 |
Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Arthritis, Reactive; Body Weight; Ciprofloxa | 1996 |
Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration.
Topics: Animals; Anti-Infective Agents; Biological Availability; Body Weight; Chromatography, High Pressure | 1996 |
Acute and subchronic toxicity studies of the new quinolone antibacterial agent irloxacin in rodents.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dose-Response Rela | 1999 |
The comparative arthropathy of fluoroquinolones in dogs.
Topics: Animals; Anti-Infective Agents; Body Weight; Ciprofloxacin; Dogs; Eating; Fluoroquinolones; Joint Di | 1999 |
The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Biopsy; Body Weight; Chronic Disease; Ciprofloxacin; | 2000 |
Case problem: medical nutrition therapy for a patient with Crohn's disease.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Body Weight; Ciprofloxacin; Crohn Disease; Diarrhea | 2000 |
Subchronic toxicity of the new quinolone antibacterial agent irloxacin in beagle dogs.
Topics: Animals; Anti-Infective Agents; Blood Cell Count; Body Weight; Ciprofloxacin; Dogs; Electrolytes; En | 2000 |
Evaluation of cardiac subacute toxicity of ciprofloxacin in rats using serum biochemical parameters.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aspartate Aminotransferases; Biomarkers; Body Weig | 2001 |
Protective effects of ciprofloxacin against type II collagen induced arthritis in rats.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Animals; Arthritis; Body Weight; Ciprofloxacin; Collagen; Do | 1992 |
In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Body Weight; Ciprofloxacin; Erythromycin; Flu | 1990 |
Single and multiple dose pharmacokinetics of ciprofloxacin.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Body Weight; Ciprofloxacin; Drug Administration | 1986 |
Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
Topics: Adult; Aged; Body Weight; Ciprofloxacin; Creatinine; Female; Humans; Kidney; Kidney Diseases; Kineti | 1986 |